the Effect Between Platelet Reactivation and Antiplatelet Drugs
|ClinicalTrials.gov Identifier: NCT02198053|
Recruitment Status : Unknown
Verified July 2015 by quan li, Beijing Anzhen Hospital.
Recruitment status was: Active, not recruiting
First Posted : July 23, 2014
Last Update Posted : July 22, 2015
|Condition or disease|
|Drug Effect Disorder Platelet Procoagulant Activity Deficiency|
All admission patients were divided into two groups, the first group were prescribed loading dose (180 mg) ticagrelor, the second group were prescribed with 90 mg ticagrelor. We measured both platelet activity and platelet reactivity using the LTA at baseline, pre-operation and post-operation. All bleeding or dyspnea events were recorded in hospital period.
Primary endpoints: platelet activity, platelet reactivity using the LTA and safety events were recorded in hospital period.
|Study Type :||Observational [Patient Registry]|
|Estimated Enrollment :||74 participants|
|Observational Model:||Case Control|
|Target Follow-Up Duration:||1 Year|
|Official Title:||Effect of 180 mgTicagrelor Compared With 90 mg Ticagrelor on Platelet Reactivity in Patients Undergoing Elective PCI.|
|Study Start Date :||May 2014|
|Estimated Primary Completion Date :||December 2015|
|Estimated Study Completion Date :||December 2015|
Ticagrelor with a loading dose of 180mg followed by 90 mg twice per day
Ticagrelor with a dose of 90mg followed by 90 mg twice per day .
- Platelet reactivity [ Time Frame: 1 year ]LTA and TEG used to measure the effect of Platelet reactivity
Biospecimen Retention: Samples Without DNA
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02198053
|Beijing, China, 100029|
|Study Director:||LI QUAN, doctor||Beijing Anzhen Hospital, Capital Medical University|